Form 4 for TRDA Entrada Therapeutics, Inc.
Accepted 2023-06-30 00:00:00 ET · period of report 2023-06-29 · accession 0001689375-23-000045 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-30 | 2023-06-29 | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +8,790 | 36.7K | +31% | +$18.5K |
| D | 2023-06-30 | 2023-06-29 | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $0.00 | -8,790 | 74.7K | -11% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-29 | M | A | 8,790 | $2.10 | 36,747 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-06-29 | M | D | 8,790 | $0.00 | 74,657 | D | $2.10 · — to 2030-11-10 | 8,790 Common Stock | (F1) 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. |